



**May 21, 2022**  
Incline Village, NV

**Meeting Co-Chairs**

Arshad M. Khanani, MD, MA & Charles C. Wykoff, MD, PhD

**Program Committee Co-Chairs**

Jeffrey S. Heier, MD & Peter K. Kaiser, MD

**Program Committee Members**

David S. Boyer, MD; Diana V. Do, MD; Frank G. Holz, MD; Anat Loewenstein, MD;  
Srinivas R. Sadda, MD; Ramin Tadayoni, MD, PhD

# AGENDA

## FRIDAY MAY 20

4:00 - 9:00 PM Registration

6:00 - 9:00 PM Dinner (Sponsored by VIAL)  
Location: Lakeside Ballroom

## SATURDAY MAY 21

6:45 AM - 5:30 PM Registration

7:00 - 8:00 AM Breakfast

8:00 - 8:05 AM Introduction Arshad Khanani & Charles Wykoff

8:05 - 8:35 AM **Starting and Managing a Successful Clinical Research Department**  
Moderator: Nancy Holekamp  
Panelists: Veeral Sheth & Jeremy Wolfe

8:05 - 8:10 AM Starting a New Retina Research Program Carl Danzig

8:10 - 8:12 AM Discussion

8:12 - 8:17 AM Building a CRO of the Future Simon Burns

8:17 - 8:19 AM Discussion

8:19 - 8:24 AM Designing Investigator Initiated Trials Caesar Luo

8:24 - 8:26 AM Discussion

8:26 - 8:31 AM Interacting with Sites and CROs as a Medical Monitor Ajay Kuriyan

8:31 - 8:33 AM Discussion

8:33 - 8:35 AM Transition

8:35 - 9:05 AM **Imaging and Functional Biomarkers**  
Moderator: Srinivas Sadda  
Panelists: Darius Moshfeghi & Quan Nguyen

8:35 - 8:40 AM Photoreceptor Degeneration as Imaging Biomarker in Dry AMD Frank Holz

8:40 - 8:42 AM Discussion

8:42 - 8:47 AM Clinical Utility of Remote Monitoring with Home OCT Judy Kim

8:47 - 8:49 AM Discussion

8:49 - 8:54 AM Update on Contrast Sensitivity Testing for Clinical Trials Karl Csaky

8:54 - 8:56 AM Discussion

8:56 - 9:01 AM OCT Angiography Endpoints for Clinical Trials Caroline Bauman

9:01 - 9:03 AM Discussion

9:03 - 9:05 AM Transition

9:05 – 9:35 AM	<b>Clinical Trials Addressing Dry AMD</b> <i>Moderator: Dante Pieramici</i> <i>Panelists: Ninel Gregori &amp; Srinivas Sadda</i>	
9:05 – 9:10 AM	Review of Clinical Findings from GATHER Trials	Julie Clark
9:10 – 9:12 AM	Discussion	
9:12 – 9:17 AM	Overview of Pegcetacoplan for GA	Federico Grossi
9:17 – 9:19 AM	Discussion	
9:19 – 9:24 AM	Targeting RNA with Antisense Therapy for Treatment of GA	Nikolas London
9:24 – 9:26 AM	Discussion	
9:26 – 9:31 AM	Treatment of GA: Multiple Ongoing Exciting Programs	Anat Loewenstein
9:31 – 9:33 AM	Discussion	
9:33 – 9:35 AM	Transition	
<b>9:35 – 9:50 AM</b>	<b>Sponsor Talk: Iveric Bio</b>	
9:50 – 10:20 AM	<b>Funding for Early-Stage Ventures: The Truth Behind the Mirrors</b> <i>Moderator: Emmett Cunningham</i> <i>Panelists: Steve Charles &amp; Anupam Dalal</i>	
9:50 – 9:55 AM	Requirements of Venture Funding for Early Stage Companies	Robert Avery
9:55 – 9:57 AM	Discussion	
9:57 – 10:02 AM	Role of KOLs in Helping Early Stage Companies	Eliot Lazar
10:02 – 10:04 AM	Discussion	
10:04 – 10:09 AM	Steps Needed to Make an Idea a Reality	Darius Moshfeghi
10:09 – 10:11 AM	Discussion	
10:11 – 10:16 AM	The Value of Big Data Analysis for Clinical Trials	Theodore Leng
10:16 – 10:18 AM	Discussion	
10:18 – 10:20 AM	Transition	
<b>10:20 – 10:30 AM</b>	<b>Break</b>	
10:30 – 11:00 AM	<b>Clinical Trials Utilizing Surgical Delivery and Devices</b> <i>Moderator: Judy Kim</i> <i>Panelists: Allen Ho &amp; Rahul Khurana</i>	
10:30 – 10:35 AM	Stem Cell-Based Therapeutic Approach for GA	Steve Charles
10:35 – 10:37 AM	Discussion	
10:37 – 10:42 AM	PDS for nAMD and DME Update	Carlos Quezada Ruiz
10:42 – 10:44 AM	Discussion	
10:44 – 10:49 AM	ATMOSPHERE and ASCENT: RGX-314 Phase 3 Update	Sherri Van Everen
10:49 – 10:51 AM	Discussion	
10:51 – 10:56 AM	Suprachoroidal CLSTA for Uveitic Macular Edema	Eduardo Uchiyama
10:56 – 10:58 AM	Discussion	
10:58 – 11:00 AM	Transition	

# AGENDA

11:00 – 11:30 AM

## **Gene Therapy for Retinal Diseases**

*Moderator: Arshad Khanani*

*Panelists: Ninel Gregori & Glenn Yiu*

11:00 – 11:05 AM

Intravitreal Gene Therapy for nAMD

David Boyer

11:05 – 11:07 AM

Discussion

11:07 – 11:12 AM

Suprachoroidal Gene Therapy for nAMD

Peter Campochiaro

11:12 – 11:14 AM

Discussion

11:14 – 11:19 AM

Gene Therapy for Inherited Retinal Diseases

Susan Washer

11:19 – 11:21 AM

Discussion

11:21 – 11:26 AM

GT005 Gene Therapy for Dry AMD

Nadia Waheed

11:26 – 11:28 AM

Discussion

11:28 – 11:30 AM

Transition

11:30 AM – 12:00 PM

## **Clinical Trials Addressing nAMD Session #1**

*Moderator: David Boyer*

*Panelists: Margaret Chang & Christina Weng*

11:30 – 11:35 AM

KSI-301 for nAMD: Pivotal DAZZLE Trial Results

Carl Regillo

11:35 – 11:37 AM

Discussion

11:37 – 11:42 AM

Update on OPT-302 for nAMD

Joel Naor

11:42 – 11:44 AM

Discussion

11:44 – 11:49 AM

Real World Experience with Faricimab: TRUCKEE Study

Arshad Khanani

11:49 – 11:51 AM

Discussion

11:51 – 11:56 AM

High Dose Aflibercept for nAMD

Diana Do

11:56 – 11:58 AM

Discussion

11:58 AM – 12:00 PM

Transition

12:00 – 12:10 PM

## **Lifetime Achievement Award - Industry: "The Summit of Excellence"**

**12:10 – 1:10 PM**

## **Lunch Symposium: Sustained Delivery for Retinal Diseases**

*Moderator: Allen Ho*

*Panelists: Richard Beckman, Christopher Brittain, Thomas Ciulla, Steve Pakola, Ram Palanki, Dante Pieramici*

**Lunch Sponsored by: REGENXBIO, Inc.**

1:10 – 1:40 PM

## **First Time Results of Clinical Trials**

*Moderator: Charles Wykoff*

*Panelists: Karl Csaky & Nancy Holekamp*

1:10 – 1:17 PM

ReCLAIM-2 Study Topline Results: Elamipretide Safety and Efficacy in Geographic Atrophy

Jeffrey Heier

1:17 – 1:19 PM

Discussion

1:19 – 1:26 PM

RZ-402: A Novel Orally Administered Plasma Kallikrein Inhibitor Targeting Diabetic Macular Edema

Raj Agrawal

1:26 – 1:28 PM

Discussion

1:28 – 1:35 PM	Beyond VEGF: Preliminary Part A Results of the INTEGRAL (THR-687) Trial	Veeral Sheth
1:35 – 1:37 PM	Discussion	
1:37 – 1:40 PM	Transition	
1:40 – 2:10 PM	<b>Clinical Trials Addressing DME</b> <i>Moderator: Jeremy Wolfe</i> <i>Panelists: Carl Danzig &amp; Yasha Modi</i>	
1:40 – 1:45 PM	OCS-01 for DME: Update on Phase 3 DIAMOND Study	Ramin Tadayoni
1:45 – 1:47 PM	Discussion	
1:47 – 1:52 PM	Faricimab for DME: Learnings from YOSEMITE/RHINE	Roger Goldberg
1:52 – 1:54 PM	Discussion	
1:54 – 1:59 PM	Brolucizumab for DME: Clinical Trial Results	Mark Barakat
1:59 – 2:01 PM	Discussion	
2:01 – 2:06 PM	Update on NEW DAY Clinical Trial	David Almeida
2:06 – 2:08 PM	Discussion	
2:08 – 2:10 PM	Transition	
<b>2:10 – 2:20 PM</b>	<b>Sponsor Talk: Genentech, Inc.</b>	
2:20 – 2:50 PM	<b>Clinical Trials Addressing nAMD Session #2</b> <i>Moderator: Diana Do</i> <i>Panelists: Caroline Baumal &amp; Carl Regillo</i>	
2:20 – 2:25 PM	Update on GB-102 for nAMD	Parisa Zamiri
2:25 – 2:27 PM	Discussion	
2:27 – 2:32 PM	Phase 1 Data from EYP-1901 Clinical Trial for nAMD	Sophie Bakri
2:32 – 2:34 PM	Discussion	
2:34 – 2:39 PM	Update on OTX-TKI for nAMD	Andrew Moshfeghi
2:39 – 2:41 PM	Discussion	
2:41 – 2:46 PM	Overview of Phase 1/2a Clinical Trial of CLS-AX	Nancy Holekamp
2:46 – 2:48 PM	Discussion	
2:48 – 2:50 PM	Transition	
2:50 – 3:20 PM	<b>Programs in Early Stage Development</b> <i>Moderator: Jeffrey Heier</i> <i>Panelists: Sophie Bakri &amp; Quan Nguyen</i>	
2:50 – 2:55 PM	A Novel Treatment for GA: HTRA1 Inhibition with IC-500	Hemant Khanna
2:55 – 2:57 PM	Discussion	
2:57 – 3:02 PM	RO-634: A Novel Bi-Specific Antibody for Retinal Diseases	Ramanath Bhandari
3:02 – 3:04 PM	Discussion	

# AGENDA

3:04 - 3:09 PM	Update on UBX1325 for Retinal Diseases	Raj Maturi
3:09 - 3:11 PM	Discussion	
3:11 - 3:16 PM	Dry AMD Therapies in Late Preclinical/ Early Stage Development	Peter Kaiser
3:16 - 3:18 PM	Discussion	
3:18 - 3:20 PM	Transition	
3:20 - 3:30 PM	Break	
3:30 - 4:00 PM	<b>Challenges of Bringing Novel Treatments to Market</b> <i>Moderator: Peter Kaiser</i> <i>Panelists: Cedric Francois, Tom Graney, Reenie McCarthy, Dario Paggiarino, Tanja Powers, Glenn Sblendorio</i>	
4:00 - 4:10 PM	<b>Sponsor Talk: Apellis Pharmaceuticals</b>	
4:10 - 4:40 PM	<b>Clinical Trials Addressing Diabetic Retinopathy</b> <i>Moderator: Glenn Yiu</i> <i>Panelists: Robert Avery &amp; Raj Maturi</i>	
4:10 - 4:15 PM	Suprachoroidal RGX-314 for Diabetic Retinopathy	Rahul Khurana
4:15 - 4:17 PM	Discussion	
4:17 - 4:22 PM	Clinical Trials for Radiation Retinopathy	Prithvi Mruthyunjaya
4:22 - 4:24 PM	Discussion	
4:24 - 4:29 PM	Phase 2 Masked Safety of Novel Oral Drug APX3330 for DR	David Lally
4:29 - 4:31 PM	Discussion	
4:31 - 4:36 PM	Assessing Retinal Perfusion and Possible Targets	Michael Ip
4:36 - 4:38 PM	Discussion	
4:38 - 4:40 PM	Transition	
4:40 - 5:10 PM	<b>Clinical Trial Failures: What Have We Learned?</b> <i>Moderator: Pravin Dugel</i> <i>Panelists: David Boyer, Jeffrey Heier, Peter Kaiser, Arshad Khanani, Christina Weng, Charles Wykoff</i>	
5:10 - 5:20 PM	<b>Lifetime Achievement Award - Physician: "The Summit of Excellence"</b>	
5:20 - 5:30 PM	Video Awards and Closing Remarks Jeffrey Heier, Peter Kaiser, Arshad Khanani, & Charles Wykoff	
5:30 - 9:00 PM	Dinner	

# SPONSORS



## DIAMOND

Iveric Bio

## GOLD

Apellis Pharmaceuticals  
Genentech, Inc.

## SILVER

AGTC  
EyePoint Pharmaceuticals  
Graybug Vision  
Gyroscope Therapeutics  
Opthea  
Oxurion

Regeneron Pharmaceuticals, Inc.  
REGENXBIO, Inc.  
Rezolute, Inc.  
Stealth BioTherapeutics  
Vial

## BRONZE

Adaptive Sensory Technology  
Adverum Biotechnologies, Inc.  
Alimera Sciences, Inc.  
Allergan, an AbbVie Company  
Bausch + Lomb  
Boehringer Ingelheim  
Broadwing Bio

Clearside Biomedical  
Ionis Pharmaceuticals, Inc.  
Kodiak Sciences  
Lexitas Pharma Services, Inc.  
NGM Biopharmaceuticals  
Notal Vision

Novartis Pharmaceuticals  
Ocular Therapeutix, Inc.  
Oculis  
Ocuphire Pharma, Inc.  
Ora, Inc.  
Recens Medical, Inc.  
Trial Runners

## ADDITIONAL SPONSOR

InFocus Clinical Research

## MEDIA PARTNER

Retina Today/EyeTube

**mcpi**

MEDICAL  
CONFERENCE  
PLANNERS  
INTERNATIONAL

[cts@medconfs.com](mailto:cts@medconfs.com)  
[ctsretina.org](http://ctsretina.org)